CNBC-TV18 learns from sources that there is no threat of a rollback of the pharma proposals already approved by the Foreign Investment Promotion Board (FIPB).
Also Read: Adulterated drugs: SC dismisses PIL against Ranbaxy According to finance ministry sources the proposals which were cleared by the FIPB on the May 10, will not be deferred. FIPB will also consider new pharma proposals at its July 5 meeting. The 10 proposals to be considered on July 5 include Mylan and GlaxoSmithKline Pharmaceuticals proposals also. Also read: GSK Consumer to focus on specialist oral care portfolioDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
